KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Deferred Taxes (2022 - 2024)

Nektar Therapeutics has reported Deferred Taxes over the past 3 years, most recently at -$31000.0 for Q3 2024.

  • Quarterly results put Deferred Taxes at -$31000.0 for Q3 2024, down 106.67% from a year ago — trailing twelve months through Sep 2024 was $1.7 million (up 99.3% YoY), and the annual figure for FY2023 was -$140000.0, down 105.17%.
  • Deferred Taxes for Q3 2024 was -$31000.0 at Nektar Therapeutics, down from $57000.0 in the prior quarter.
  • Over the last five years, Deferred Taxes for NKTR hit a ceiling of $2.7 million in Q4 2022 and a floor of -$1.8 million in Q1 2023.
  • Median Deferred Taxes over the past 3 years was -$21000.0 (2023), compared with a mean of $319500.0.
  • Peak annual rise in Deferred Taxes hit 311.11% in 2024, while the deepest fall reached 106.67% in 2024.
  • Nektar Therapeutics' Deferred Taxes stood at $2.7 million in 2022, then plummeted by 36.71% to $1.7 million in 2023, then plummeted by 101.81% to -$31000.0 in 2024.
  • The last three reported values for Deferred Taxes were -$31000.0 (Q3 2024), $57000.0 (Q2 2024), and -$38000.0 (Q1 2024) per Business Quant data.